LXEO Stock Forecast: Lexeo Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Lexeo Therapeutics, Inc. is $23. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Lexeo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (73): Sales and profits are climbing, and climbing faster than before.
Revisions (26): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LXEO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LXEO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Cantor Fitzgerald | Maintains | Overweight | $23 → $37 |
| 12 Nov 2026 | Cantor Fitzgerald | Reiterates | Overweight | $23 |
| 23 Sept 2026 | Leerink Partners | Maintains | Outperform | $15 |
| 25 June 2026 | JP Morgan | Maintains | Overweight | $12 → $9.00 |
| 11 May 2026 | Chardan Capital | Maintains | Buy | — |
| 13 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 13 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Dec 2025 | Raymond James | Initiates | Strong Buy | — |
| 11 Dec 2025 | Chardan Capital | Maintains | Buy | — |
| 1 Dec 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 20 Nov 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 6 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 5 Nov 2025 | Chardan Capital | Maintains | Buy | $17 |
| 21 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Oct 2025 | Guggenheim | Initiates | Buy | — |
| 7 Oct 2025 | Chardan Capital | Maintains | Buy | — |
| 7 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Oct 2025 | Leerink Partners | Maintains | Outperform | — |
| 15 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 15 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LXEO.
This page is one stock. Monday covers all of them.
LXEO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LXEO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Lexeo Therapeutics, Inc. returned −66.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
LXEO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.1×
- EV / EBITDA
- —
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −62.4%
- Return on assets
- −36.7%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lexeo Therapeutics, Inc. has a market value of $245.1M and an enterprise value of $56.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$87.3M.
Diluted earnings per share, trailing twelve months: −$1.15.
Free cash flow in the twelve months to 30 June 2026: −$88.7M.
Lexeo Therapeutics, Inc. employs 68 people.
Data provided by Twelve Data
LXEO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LXEO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Lexeo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LXEO
What is the LXEO stock price forecast for 2026-2027?
The median 12-month analyst price target for Lexeo Therapeutics, Inc. is $23, with estimates ranging from $9 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LXEO stock a buy right now?
Of the 9 analysts covering Lexeo Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexeo Therapeutics, Inc. 30 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LXEO?
As at 21 Nov 2026, Lexeo Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (73 of 100).
Will LXEO stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts is $23, and Ticker Nerd's factor model ranks Lexeo Therapeutics, Inc. 30 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LXEO stock forecast for 2030?
No analyst covering Lexeo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $42 over the next 12 months.
How has LXEO stock performed over the past year?
Lexeo Therapeutics, Inc. returned -66.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Lexeo Therapeutics, Inc. do?
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need. Lexeo Therapeutics concentrates on genetically defined cardiovascular conditions and APOE4-associated Alzheimer’s disease, using AAV-based programs designed to address the underlying causes of disease.
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing gene therapy candidates for hereditary and acquired diseases with high unmet medical need. Lexeo Therapeutics concentrates on genetically defined cardiovascular conditions and APOE4-associated Alzheimer’s disease, using AAV-based programs designed to address the underlying causes of disease. Its current pipeline includes therapies such as LX2006 for Friedreich’s ataxia cardiomyopathy, LX2020 for PKP2-related arrhythmogenic cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer’s disease. The company operates as a biotechnology developer rather than a commercial drug maker, with its work centered on research, clinical development, and advancing precision medicines through early- and mid-stage testing. Based in New York City, Lexeo Therapeutics plays a specialized role in the genetic medicine market by targeting serious conditions where conventional treatments remain limited.
CEO Mr. R. Nolan Townsend M.B.A. · 68 employees · United States · https://www.lexeotx.com